NXTC

+ Watchlist + Portfolio

NextCure, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.78
52-Week Range: $1.55 – $15.74
Market Cap: $28.61M
P/E (TTM): —
EPS (TTM): -7.67
Dividend Yield: —

Advanced Metrics

Price/Book: 2.09
PEG Ratio: —
Return on Equity: -204.56%
Return on Assets: -69.02%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 3.47
Debt/Equity: 0.38
Total Debt: $4.67M
Free Cash Flow: $-23.10M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $13.19M

NXTC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$54.20M	$47.93M	$41.49M	$44.92M
Selling, General & Admin	$21.71M	$19.71M	$15.72M	$12.69M
Operating Expenses	$75.91M	$67.64M	$57.21M	$57.62M
Operating Income	-$75.91M	-$67.64M	-$57.21M	-$57.62M
EBITDA	-$71.78M	-$63.95M	-$54.34M	-$55.43M
Pretax Income	-$74.73M	-$62.72M	-$55.65M	-$55.84M
Net Income	-$74.73M	-$62.72M	-$55.65M	-$55.84M
Diluted EPS	-32.28	-27.00	-23.88	-19.65
Diluted Shares	2.31M	2.32M	2.33M	2.84M

NXTC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$26.63M	$13.08M	$27.73M	$25.98M
Current Assets	$163.98M	$112.72M	$71.81M	$43.75M
Total Assets	$184.16M	$128.04M	$80.86M	$50.18M
Current Liabilities	$9.13M	$6.88M	$9.57M	$10.57M
Total Debt	$7.12M	$6.61M	$5.95M	$5.15M
Total Liabilities	$16.63M	$13.62M	$15.39M	$15.24M
Retained Earnings	-$261.76M	-$324.48M	-$380.14M	-$435.98M
Shareholders' Equity	$167.53M	$114.42M	$65.47M	$34.94M
Working Capital	$154.86M	$105.84M	$62.23M	$33.18M

NXTC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$53.89M	-$52.97M	-$40.80M	-$49.61M
Capital Expenditure	-$2.12M	-$820.00K	-$474.00K	—
Free Cash Flow	-$56.00M	-$53.79M	-$41.28M	-$49.61M
Depreciation & Amortisation	$4.12M	$3.68M	$2.87M	$2.19M
Stock-Based Compensation	$9.51M	$8.19M	$6.33M	$2.99M
Investing Cash Flow	$67.98M	$39.27M	$55.31M	$25.56M
Financing Cash Flow	$200.00K	$154.00K	$144.00K	$22.31M
Net Change in Cash	$14.29M	-$13.55M	$14.64M	-$1.75M

NXTC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.90M	$24.09M	$6.14M	$6.80M	$6.83M
Selling, General & Admin	$3.73M	$3.20M	$2.81M	$2.96M	$3.27M
Operating Expenses	$11.62M	$27.29M	$8.95M	$9.76M	$10.11M
Operating Income	-$11.62M	-$27.29M	-$8.95M	-$9.76M	-$10.11M
EBITDA	-$10.97M	-$26.66M	-$8.41M	-$9.39M	-$9.82M
Pretax Income	-$10.98M	-$26.81M	-$8.62M	-$9.44M	-$9.80M
Net Income	-$10.98M	-$26.81M	-$8.62M	-$9.44M	-$9.80M
Diluted EPS	-4.70	-11.29	-3.22	—	-1.87
Diluted Shares	2.33M	2.37M	2.68M	—	5.24M

NXTC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$21.83M	$4.89M	$7.32M	$25.98M	$15.17M
Current Assets	$58.90M	$40.02M	$32.64M	$43.75M	$31.74M
Total Assets	$67.14M	$47.69M	$39.61M	$50.18M	$37.98M
Current Liabilities	$5.74M	$10.78M	$10.99M	$10.57M	$6.89M
Total Debt	$4.91M	$4.67M	$4.41M	$5.15M	$3.88M
Total Liabilities	$11.28M	$16.04M	$15.97M	$15.24M	$11.26M
Retained Earnings	-$391.11M	-$417.92M	-$426.54M	-$435.98M	-$445.78M
Shareholders' Equity	$55.85M	$31.65M	$23.65M	$34.94M	$26.72M
Working Capital	$53.16M	$29.23M	$21.64M	$33.18M	$24.85M

NXTC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$12.99M	-$22.71M	-$6.27M	-$7.64M	-$13.36M
Free Cash Flow	-$12.99M	-$22.71M	-$6.27M	-$7.64M	-$13.36M
Depreciation & Amortisation	$654.00K	$633.00K	$533.00K	$365.00K	$283.00K
Stock-Based Compensation	$1.36M	$588.00K	$600.00K	$435.00K	$344.00K
Investing Cash Flow	$7.09M	$3.76M	$8.70M	$6.00M	$1.30M
Financing Cash Flow	$0.00	$2.02M	$0.00	$20.29M	$1.25M
Net Change in Cash	-$5.90M	-$16.93M	$2.43M	$18.66M	-$10.81M

Market Snapshot

About

NextCure is an immuno-oncology biotechnology company developing novel immunomedicines to treat cancer and other immune-related diseases. The company focuses on modulating the immune system to improve patient outcomes.